Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 38Genitourinary 16Gastrointestinal 13Breast 10Thoracic 8Other solid neoplasm 6Head & Neck 5CNS 5Tumor-Agnostic 4Sarcoma 3Dermatologic 3Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma 1Pathologic Complete Response 1Neoplasms 1Leiomyosarcoma 1Hemangiosarcoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 93Doxorubicin 92Radiotherapy 87Temozolomide 69Filgrastim 58Ifosfamide 55Bevacizumab 55Etoposide 48Gemcitabine 44Imatinib Mesylate 43Vincristine 40pembrolizumab 35pazopanib 34Peripheral Blood Stem Cell Transplantation 31Methotrexate 31Nivolumab 30Carboplatin 30fludarabine phosphate 29Irinotecan 29Cisplatin 28Paclitaxel 26Melphalan 26Magnetic Resonance Spectroscopy 26Docetaxel 25Busulfan 25Trabectedin 24apatinib 22Specimen Handling 21Sirolimus 21Antilymphocyte Serum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × niraparib × Sarcoma × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05515575 2025-10-20

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
8 enrolled
Sarcoma

Sarcoma

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
Sarcoma

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡